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ABSTRACT
A solid tumor consists of cancer and stromal cells, which comprise the tumor microenvironment (TME).
Tumor-associated macrophages (TAMs) are usually abundant in the TME, contributing to tumor pro-
gression. In cases of peritoneal dissemination of gastric cancer (GC), the contribution of intraperitoneal
TAMs remains unclear. Macrophages from peritoneal washings of GC patients were analyzed, and the
link between intraperitoneal TAMs and GC cells was investigated to clarify the interaction between them
in peritoneal dissemination. Macrophages were predominant among leukocytes constituting the micro-
environment of the peritoneal cavity. The proportion of CD163-positive TAMs was significantly higher in
stage IV than in stage I GC. Co-culture with TAMs potentiated migration and invasion of GC. IL-6 was the
most increased in the medium of in vitro co-culture of macrophages and GC, and IL-6 elevation was also
observed in the peritoneal washes with peritoneal dissemination. An elevated concentration of intra-
peritoneal IL-6 was correlated with a poor prognosis in clinical cases. In conclusion, intraperitoneal TAMs
are involved in promoting peritoneal dissemination of GC via secreted IL-6. TAM-derived IL-6 could be
a potential therapeutic target for peritoneal dissemination of GC.
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Introduction
Gastric cancer (GC) is one of the most common malignancies
worldwide, and the third leading cause of cancer-related deaths.1
Peritoneal metastasis is a frequent mode of metastasis of GC,2,3
which leads to a serious clinical condition, resulting in dismal
consequences.4 Nevertheless, there is no definitive therapy for
the peritoneal spread of GC, mainly because the mechanism of
peritoneal metastasis has yet to be fully understood, and the
appropriate target has not been identified. Thus, to overcome
this disease entity, we still need to explore and understand the
complexity of peritoneal metastasis to develop novel strategies.
In recent years, it has been reported that TME plays a pivotal
role in cancer progression. TME consists of various components,
including extracellular matrix, endothelial cells, fibroblasts, lym-
phocytes, and macrophages.5 Of them, tissue-infiltrating macro-
phages have been found to be correlated with a poor prognosis in
several cancers.6–10 Such macrophages in the TME have been
recognized as TAMs. Macrophages display remarkable plasticity
in response to environmental cues and have a function between
two phenotypes, the classical M1 and the alternative M2
macrophages,11 in their functional spectrum. TheM1macrophages
are involved in the inflammatory response, pathogen clearance,
and antitumor immunity. Conversely, the M2 macrophages are
associated with an anti-inflammatory response, wound healing,
and pro-tumorigenic properties.12 The evidence shows that
TAMs are relatively skewed to the M2 type,13,14 and those in
solid tumors modulate the TME to make it favorable for cancer,
contributing to aggravation of their malignant phenotype and
immunoregulation.15 Although it is now recognized that macro-
phages are plastic and versatile and the concept ofM1-M2 extremes
may not capture their whole spectrum,16–19 some studies have
actually shown that TAMs promote the progression of GC.20,21
Given this evidence that the TME is associated with cancer
progression, we have an interest in how the intraperitoneal micro-
environment contributes to the development and progression of
peritoneal metastasis. Since few reports have described the interac-
tion between intraperitoneal TAMs and cancer cells, the molecular
mechanisms underlying the tumor-promoting properties of TAMs
remain unclear. Because of the difficulty of accessing the peritoneal
cavity in humans, ways to explore the intraperitoneal microenvir-
onment are limited. One of the available strategies is the investiga-
tion of cellular samples in the washes of the abdominal cavity
obtained during surgery. Based on the fact that the presence of
intraperitoneal free cancer cells is a strong factor related to an
increased risk of peritoneal recurrence, peritoneal lavage cytology
is incorporated into the staging of GC and routinely performed
during surgery for patients with advancedGC.22,23 Using peritoneal
lavage samples, the previously unappreciated numerous normal
cells co-existing with cancer cells were investigated as components
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of the intraperitoneal microenvironment, focusing particularly on
TAMs, and how the intraperitoneal microenvironment contributes
to promote peritoneal dissemination was explored.
Results
Macrophages differentiated to CD163+ TAMs are
predominant in the peritoneal cavity in the presence of
GC cells
Intraperitoneal cellular components of a GC patient with positive
cytology were investigated (Figure 1). Cancer cells were labeled with
telomerase-specific replicative adenovirus, TelomeScan.24–26 As
shown in Figure 1(a), it was confirmed that numerous CD45
+ leukocytes existed in the peritoneal cavity along with GFP-
positive cancer cells, and almost all of them were found to be
CD14+ macrophages. Furthermore, when they were stained with
anti-CD163 antibody, abundantCD163+macrophageswere present
in the surroundings of the cancer cells (Figure 1(b)). The peritoneal
wash was then further analyzed to compare the intraperitoneal
microenvironment between stage I and IV GC patients focusing
on the constituent rate of intraperitoneal macrophages by flow
cytometry (Figure 1(c,d)). The proportion of macrophages positive
for CD14 in CD45+ leukocytes (CD14/CD45) was significantly
higher in stage IV patients than in stage I patients. Moreover, the
proportion ofCD163+ cells inCD14+macrophages (CD163/CD14)
was significantly higher in stage IV patients than in stage I patients.
Of note, in the peritoneal wash from stage IGCpatients, the number
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Figure 1. Most macrophages co-existing with cancer cells in the peritoneal cavity are positive for CD163.
(a) and (b) The cells in peritoneal washes were infected with cancer-imaging adenovirus, TelomeScan. Immunofluorescent staining was added to visualize
intraperitoneal leukocytes (CD45), macrophages (CD14), and activated macrophages (CD163). (c) Representative figure of flow cytometric analysis. (d)
Summarized data of flow cytometric analysis of Stage I and Stage IV samples. The values represent medians ± standard deviation, SD. (stage I: n = 11, stage IV:
n = 15). (n.s.: not significant, *p < .01, Student’s t-test)
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of cellswas small in general, andmost of themwere stainedbyCD45,
but not byCD14 (Figure S1). These data suggest that, in the presence
of GC cells, numerous macrophages were deployed into the perito-
neal cavity and differentiated to CD163+ TAMs.
Upregulated migration and invasion ability of GC cells by
co-culture with CD163-positive TAMs
Considering such an intraperitoneal TME in clinical samples of
GC, the interaction between GC cells and TAMs was examined.
To obtain TAMs, first, CD163+ macrophages were differentiated
from THP-1 cells with IL-4 according to a differentiation
protocol27 (Figure 2(a)). GC cells were co-cultured with those
THP-1-derived macrophages (TDMs) using a biphasic chamber
to mimic the intraperitoneal environment. Since TAMs are
known to affect the malignant phenotype of cancer, 28–30 whether
TDMs increased the migration and invasion abilities of GC cells
was investigated. Consistent with the previous reports, the migra-
tion and invasion abilities of GCIY were significantly increased by
TDMs compared with the non-co-cultured group (Figure 2(b)).
Similar results were also observed in MKN45 and MKN1 cells
(Figure S2A). Next, the effects of TDMs on the chemo-sensitivity
of GC cells were investigated. After co-culture with TDMs, GC
cells tended to be insensitive to chemotherapeutic agents includ-
ing paclitaxel (Figure S3A) and 5-FU (Figure S3B), although the
difference compared to control was not significant.
These data confirmed that indirect co-culturewith TDMs inten-
sifies the malignant phenotype of GC. In addition, these phenom-
ena suggest that somekinds of humoral factorswere associatedwith
the promotion of the malignant phenotype of GC cells.
Macrophage-derived IL-6 was increased by the
interaction with GCIY
To explore how TAMs affect malignant phenotypes of GC,
the supernatants from GCIY/TDM co-cultures were examined
using an array for cytokines/chemokines in vitro. When the
relative values of cytokines and chemokines in the superna-
tant were compared, IL-6 had the highest value, which was
increased by more than 3-fold in the co-culture of TDMs and
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Figure 2. CD163+ macrophages intensify migration and invasion abilities.
(a) THP-1 cells were differentiated into macrophages. Polarized CD80+ or CD163+ macrophages were evaluated by flow cytometry. CD14: a pan-macrophage marker,
CD80: an M1-type macrophage marker, and CD163: an M2-type macrophage marker. (b) GCIY cells were stimulated with TDMs. Subsequently, migration and invasion
abilities were evaluated in comparison with the unstimulated cells. Values represent means ± SD. (n = 5 fields/well). (*p < .01, Student’s t-test)
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GCIY cells compared with the culture of TDMs alone
(Figure 3(a)). With the quantification of IL-6 by ELISA,
TDMs secreted more IL-6 on stimulation with GCIY than
GCIY or TDMs in mono-culture (Figure 3(b)). The same
results were obtained in MKN45 and NUGC3, although
KATO-III did not stimulate macrophages to secrete IL-6
(Figure S4A). Even though TDMs themselves secreted
a small amount of IL-6 depending on their cell number,
TDMs were found to secrete more IL-6 when co-cultured
with even a small amount of cancer cells (Figure 3(c)).
IL-6 mediated the JAK/STAT3 pathway and promoted the
migration and invasion abilities of GC cells
Given the fact that IL-6 was the most upregulated cytokine
secreted from macrophages by their interactions with GC cells,
whether IL-6 directly promotes the migration and invasion of GC
cells was examined. Both migration and invasion of GCIY were
accelerated, and the effect depended on the concentration of IL-6
(Figure 4(a)). The same result was also obtained in MKN45 GC
cells (Figure S2B). However, cell proliferation was not affected by
IL-6 (Figure S4B). Moreover, along with this effect, STAT3 in
GCIY was gradually phosphorylated when treated with IL-6
(Figure 4(b)) and co-cultured with TDMs (Figure 4(c)), in a
dose or cell number-dependent manner. These data imply that
IL-6 from TDMs upregulated the migration and invasion abilities
of GC cells, which would be associated with the JAK/STAT3-
mediated pathway.
Intraperitoneal microenvironment in the peritoneal
dissemination of the in vivo mouse model
GCIY-Luc or MKN45-Luc cells were injected into the perito-
neal cavity of mice, and the mouse peritoneal dissemination
models were established (Figure 5(a)). As with the clinical
peritoneal washes, saline was injected into the mouse peritoneal
cavity, and the peritoneal washes were obtained. When their
cellular components were assessed by flow cytometry (Figure 5
(b,c)), more CD14+ macrophages were induced into the peri-
toneal cavity in the presence of cancer cells, especially in GCIY-
peritoneal dissemination, than in the mock-group. Moreover,
most CD14+ macrophages were confirmed to express CD163,
although the proportion of CD163+ macrophages was also high
in the mock-group. Interestingly, the concentration of IL-6 was
a
b c
Figure 3. IL-6 is elevated with the co-culture of TDMs and GC cells.
(a) Cytokine and chemokine arrays of supernatants from transwell co-culture TDMs and GCIY cells. The values are normalized by TDMs mono-culture supernatants. (b)
IL-6 concentration in TDMs/GCIY transwell co-culture supernatants were quantified by ELISA (n = 3). As a control, each mono-culture supernatant of GCIY or TDMs
was analyzed. The values represent means ± SD. (*p < .01, Student’s t-test) (c) GCIY (1 × 104) cells were co-cultured with various numbers of TDMs (5, 10, 20, and
30 × 104). IL-6 concentrations of the co-culture supernatants were quantified. The values represent means ± SD. (*p < .01, Student’s t-test)
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markedly elevated in the peritoneal dissemination mice com-
pared to the control mice (Figure 5(d)). These results demon-
strated that CD163+ TAMs were prevalent in the peritoneal
cavity with dissemination of GC, and that IL-6 appears to be
secreted by TAMs upon their interaction with cancer cells.
In vivo effect of IL-6 for the acceleration of peritoneal
dissemination
Whether IL-6 is the factor that actually accelerates the devel-
opment of peritoneal dissemination was further assessed.
When GC cells were inoculated into the peritoneal cavity of
mice along with IL-6 recombinant protein, peritoneal dissemi-
nation was significantly enhanced in the mice compared with
the controls (Figure 5(e)). Whether neutralization of intraper-
itoneal IL-6 by an anti-mouse IL-6 antibody could inhibit the
peritoneal dissemination of GC was then investigated (Figure
S5). Blocking the IL-6-mediated pathway tended to suppress
peritoneal dissemination, although the difference between the
groups was not significant. To further investigate the intraper-
itoneal environment in the mouse peritoneal dissemination
models, the peritoneal washes collected from GCIY-Luc and
MKN45-Luc-inoculated mice were examined using an array
for humoral factors. When the relative values of cytokines,
chemokines, and angiogenic factors in the washes were
compared between mock and peritoneally disseminated mice,
elevations of various cytokines, chemokines, and angiogenic
factors other than IL-6 were also observed (Figure S6). These
data imply that IL-6 was in part associated with the promotion
of peritoneal dissemination.
Clinical correlation between IL-6 and CD163-positive
TAMs in the peritoneal cavity
Based on these observations, the peritoneal washes obtained
from stage IV and stage I GC patients were again analyzed.
The levels of IL-6 and the number of CD163+ macrophages
per ml of peritoneal wash were quantified by ELISA and flow
cytometry, respectively, and compared between stages IV and
I GC patients. It was found that IL-6 was higher (Figure 6(a))
and CD163+ macrophages were significantly more numerous
(Figure 6(b)) in stage IV patients than in stage I patients.
Moreover, when they were compared in the peritoneal dis-
semination-positive (P1) group and the cytology-positive
without peritoneal dissemination (CY1/P0) group in stage
IV patients, IL-6 was even higher, and the number of
CD163+ macrophages was even larger in the P1 group than
in the CY1/P0 group (Figure 6(c,d)). Furthermore, when stage
IV patients were divided by IL-6 positivity, a significantly
larger number of CD163+ macrophages was detected in the
a
b c
Figure 4. IL-6 potentiates migration and invasion of GC and induces phosphorylation of STAT3.
(a) Migration and invasion assay of GCIY cells treated with the medium containing IL-6 (0–100 ng/ml). Migrated and invaded cells were counted by staining with
0.5% crystal violet. The values represent means ± S. D. (*p < .01, Student’s t-test) (b) Western blotting analysis of GCIY cells treated with IL-6 at different doses
(0–100 ng/ml). (c) Western blotting analysis of GCIY cells treated with CD163+ TDMs (ratios TDMs/GCIY of 0, 2, 5, and 10).
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IL-6-positive group (Figure 6(e)). Ultimately, the survival
period of IL-6 positive patients was significantly shorter
than that of IL-6-negative patients (Figure 6(f)).
Discussion
In this study, peritoneal washes from GC patients were exam-
ined, and it was found that the majority of the cellular
components in stage IV patients were CD163+ macrophages,
which led to the hypothesis that the intraperitoneal TAMs were
associated with GC peritoneal dissemination. The indirect co-
culture of TDMs potentiated the migration and invasion abilities
of GC cells. Interestingly, among the various cytokines and
chemokines, IL-6 was found to show the highest relative increase
in the medium of in vitro co-culture of macrophages and GC.
The concentration of IL-6 was higher in the ascites fluid of mice
b c
d
a
e
Figure 5. In vivo model of peritoneal dissemination.
(a) GCIY-Luc and MKN45-Luc cells were inoculated into the peritoneal cavity of BALB/C nu/nu mice (n = 5/group). Peritoneal dissemination was quantified by IVIS
once a week. (b) Peritoneal washes were collected at 21 days after inoculation. Peritoneal macrophages were evaluated by flow cytometry. (c) The proportions of
CD14/CD45 and CD163/CD14 are summarized. The values represent means ± SD. (*p < .01, Student’s t-test) (d) IL-6 in the peritoneal wash was quantified. The value
of IL-6 at less than detectable sensitivity was defined as one. (*p < .01, Wilcoxon-test) (e) IL-6 promotes peritoneal dissemination in the GCIY-Luc xenografted model.
GCIY-Luc cells were inoculated into the peritoneal cavity of BALB/C, nu/nu, mice (n = 9-10/group). Subsequently, human IL-6 recombinant protein (200 ng/200 μl/
body) or PBS (200 μl/body) was inoculated twice a week, and peritoneal dissemination was quantified by IVIS once a week. The values represent means ± standard
error of the mean, SEM. (*p < .05, Student’s t-test)
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with peritoneal dissemination than in those without it. The
results suggest that IL-6 secreted from TAMs must be one of
the key mediators that accelerates the peritoneal dissemination
of GC.
Macrophages have been recognized as regulators of the
complex TME, where they exhibit either pro-tumor or anti-
tumor functions. Considering macrophage phenotype classi-
fication by the M1-M2 paradigm, TAMs are generally thought
to be much closer to M2-polarized macrophages, but macro-
phages actually show a spectrum of activation states rather
than such dichotomous phenotypes.16 Since in vivo macro-
phages in particular do not so neatly divide into the M1 and
M2 classification schemes, there is an effort to avoid the
ambiguity of the M1-M2 characterization of TAMs.16–19
Therefore, in the present study, use of “M1” and “M2” for
the macrophages observed in this study was avoided.
a b
c d
e f IL-6 positive IL-6 negative
p < 0.05 (log rank)
Figure 6. Clinical correlation between IL-6 and TAMs in the peritoneal cavity.
(a) and (b) The levels of IL-6 and CD163+ macrophages were evaluated in stage I and stage IV patients. (c) and (d) The levels of IL-6 and CD163+ macrophages
were compared between cytology-positive only and peritoneal dissemination-positive patients.A value of IL-6 less than detectable sensitivity was defined as one.
A value greater than 4 pg/ml, which is a serum reference value, was defined as positive. The values represent means ± SD. (*p < .01, ** p < .05, Pearson’s chi-squared
test). The absolute value of CD163-positive TAMs per ml of peritoneal wash was also measured. Values represent means ± SD. (*p < .01, **p < .05 Wilcoxon test)
Correlations of IL-6 and CD163+ macrophages with the prognosis of GC patients(e) Stage IV GC patients were divided into groups according to IL-6 positivity,
and the numbers of intraperitoneal CD163+ macrophages were compared. A value greater than 4 pg/ml, which is a serum reference value, of IL-6 was defined as
positive. (*p < .05, Wilcoxon test) (f) Survival curves were estimated using the Kaplan-Meier method and compared using the log-rank test. p < .05 was considered
significant.
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Although it has been reported that TAMs secrete some pro-
tumor factors in the TME, 12 IL-6 can also be one.31,32 IL-6 is
known to be a multifunctional cytokine, 33 and its stimulation
induces homo-dimerization of gp130, phosphorylating JAKs
and STAT3 after binding IL-6 receptor, and then phosphory-
lated STAT3 transfers the signals to its downstream .34 IL-6
would thus contribute to promoting some kinds of malignant
phenotype in many cancers .35 Based on the result shown in
Figure 3(c), it was assumed that the macrophages produced IL-
6, because when TDMs were co-cultured with even a certain
and small amount of cancer cells, more TDMs secreted more
IL-6. The previous studies demonstrated that the main produ-
cers of IL-6 are the myeloid cells.32,36 However, autocrine IL-6
in epithelial cancer cells has also been documented.37,38 Thus,
GC cells may also secrete IL-6 under certain conditions.
In the present experiment, by co-culturewithCD163+macro-
phages or with IL-6, the migration and invasion abilities (Figures
2(b) and 4(a), S2A, and S2B) of GC cells were potentiated.
Phosphorylation of STAT3 in GCIY co-cultured with macro-
phages also suggested the involvement of IL-6 (Figure 4(b)).
Other groups reported that IL-6 is involved in metastasis
through inducing the epithelial mesenchymal transition (EMT)
in many cancer tissues, such as pancreatic cancer, colorectal
cancer, head and neck cancer, cervical cancer, and ovarian
cancer, as well as GC.39–44 As we recently demonstrated in
pancreatic cancer,30 the intensification of the malignant traits
of intraperitoneal GC might be associated with the EMT.
In themouse peritoneal disseminationmodel, CD163+TAMs
were predominant in the peritoneal cavity in the presence of
cancer cells (Figure 5(a–c)). In even the mock group, peritoneal
macrophages were also predominantly CD163+ cells (Figure 5
(c)). According to the previous reports, the peritoneal microen-
vironment is supposed to be a hypoxic, lactic, and starved
condition,45 which might affect the macrophages’
phenotype.46–48 In the clinical peritoneal washes, there was
a certain percentage of CD163+ macrophages even in stage I,
but the absolute numbers of macrophages were definitely higher
in stage IV than in stage I (Figure 6(b)). Moreover, the striking
difference in the peritoneal cavity between stage I and IV was the
concentration of IL-6 (Figure 6(a)). These data suggest that more
macrophages were induced into the peritoneal cavity by emer-
ging cancer cells, and they preferentially differentiated to CD163
+ TAMs, secreting a large amount of IL-6 through their interac-
tion with them. Further supporting that, in stage IV patients,
a significantly larger number of CD163+ TAMs and a larger
amount of IL-6 were detected in the P1 group than in the CY1/
P0 group (Figure 6(a,d)). Finally, the IL-6-positive group had
a significantly larger number of CD163+TAMs (Figure 6(e)) and
a worse prognosis (Figure 6(f)) than the IL-6-negative group.
Previous studies have reported that serum IL-6 is a prognostic
biomarker in many cancers, such as GC,49 pancreatic cancer,50
lung cancer,51 prostate cancer,52 and renal cell carcinoma.53 The
present data showing the correlation between intraperitoneal IL-
6 and prognosis might be concordant with these previous
reports. Collectively, these data imply that CD163+ TAMs con-
tribute to promoting peritoneal dissemination by secreting IL-6
after their interaction with free cancer cells.
The in vivo effect of IL-6, as well as anti-IL-6 antibody,
on the formation of peritoneal dissemination was evalu-
ated in the mouse model. Recombinant IL-6 accelerated
the expansion of peritoneal dissemination (Figure 5(e)),
and anti-mouse IL-6 antibody tended to suppress the
expansion of peritoneal dissemination (Figure S5). IL-6
was reported to be associated with the activation of nat-
ural killer T cells, 54 and, thus, it is possible that the
correlation between IL-6 and the formation of peritoneal
dissemination is related to the activity of natural killer
T cells.55
This study has potential limitations that need to be addressed.
First, THP-1 acute monocytic leukemia cells were used as a model
for human monocytes.56 These cells have been widely used to
investigate the function ofmonocytes andmacrophages, but some
differences relative to human peripheral blood monocytes have
been identified.57,58 For example, the THP-1 cells express lower
levels of CD14 and are less responsive to LPS than primary
monocytes.59 Though THP-1-derived macrophages might not
entirely mimic primary monocytes, the cells exhibit some of the
functions of macrophages, as previous studies demonstrated.
However, it is important to interpret the study results keeping in
mind that the findings were obtained fromTHP-1-derived cells. It
is desirable to validate the results in this study under other con-
ditions to draw more definite conclusions. Second, “M2-like”
CD163+ cells were mainly used, and M1-like cells were not
investigated. M1-like polarized cells may also produce IL-6.19
The accumulating evidence shows that TAMs have a spectrum
of different activation states and share phenotypes of bothM1 and
M2. Thus, the intraperitoneal TME would be more dynamic and
complex than the experimental models. Third, common problems
in cell culture experiments must be taken into account to interpret
the results, such as genetic instability and contamination with
microorganisms that propagating cell lines might have. The cells
used in the present study were not tested for mycoplasma.
However, only cells purchased directly from commercial provi-
ders were used, using cells of as low passages as possible, usually
less than 10 passages. Therefore, these efforts would have mini-
mized fluctuations in the experimental results.
Based on these results, macrophage-targeting anti-tumor
treatment approaches might be potential candidates, and they
have actually been under clinical investigation.60 The agents
in clinical trials targeting macrophages in tumors include
CSF-1R inhibitors, anti-CD47 antibodies, and a CCR2 antago-
nist, although few approaches targeting IL-6 are also clinically
available. Of note, the anti-tumor efficacy of blockade of IL-6
signaling with tocilizumab, a drug approved for the treatment
of rheumatoid arthritis, was demonstrated for pancreatic
cancer61 and hepatocellular carcinoma.32 However, since toci-
lizumab has not yet been evaluated for its efficacy in perito-
neal dissemination of GC, further study will be needed.
In conclusion, macrophages were skewed to CD163+ TAMs in
the peritoneal cavity, and their co-existence with GC cells made
them secrete IL-6. These TAMs accelerate the formation of perito-
neal dissemination via an IL-6/STAT3-mediated pathway, and
intraperitoneal IL-6 was found to be a prognostic factor for
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survival. Targeting intraperitoneal TAM-derived IL-6 might be
a novel therapeutic strategy to overcome peritoneal dissemination
in GC patients.
Material and methods
Clinical peritoneal washes
Peritoneal washes were obtained from GC patients during
surgery performed in our hospital,30,62 including 15 stage IV
patients and 11 stage I patients. The samples were prospec-
tively collected from all patients who gave their informed
consent to participate in the study, and those used in this
study were selected retrospectively and almost consecutively
from the latest one, in consideration of the stock status and
clinical stages. The clinicopathological data were obtained
from the medical records, and the cancers were staged in
accordance with the Japanese Classification of Gastric
Carcinoma: 3rd English edition.63 The clinicopathological
characteristics of these patients are presented in supplemen-
tary tables A and B. The samples were centrifuged at
1500 rpm, 24°C for 3 minutes, and the supernatants were
preserved at −80°C for the later experiments. For the cell
sediment analysis, red blood cells were removed with RBC
lysis buffer (BioLegend, #420301), and the other cellular com-
ponents were analyzed by flow cytometry.
Cell lines and cell cultures
A human monocytic leukemia cell line, THP-1, was purchased
from the American Type Culture Collection and cultured in
RPMI-1640 medium (Sigma-Aldrich, #R8758) supplemented
with 10% fetal bovine serum (FBS) and 1% penicillin/strepto-
mycin (P/S). The macrophage-like state was obtained by treating
THP-1 with 100 ng/ml phorbol 12-myristate 13-acetate (PMA)
(Sigma-Aldrich, #P8139) for 48 hours. Polarized, adherent cells
were washed and rested for 24 hours in the culture medium to
obtain the resting state of macrophages. These resting macro-
phages were primed for 24 hours with fresh medium supple-
mented with interferon-γ (20 ng/ml; Sigma-Aldrich, #I3265) +
c (1 μg/ml; Sigma-Aldrich) to polarize into the M1 phenotype
and with IL-4 (20 ng/ml; Sigma-Aldrich, #SRP4137) to polarize
into the M2-like phenotype.27 The human GC cell line GCIY
(poorly differentiated adenocarcinoma) was purchased from the
Cell Engineering Division of RIKEN BioResource Center
(RIKEN Cell Bank). GCIY-Luc, expressing luciferase, was estab-
lished in our laboratory. GCIY cells were cultured in MEM
(Sigma-Aldrich, #M4655) supplemented with 15% FBS and 1%
P/S. GENETICIN (800 μg/ml) was additionally added in GCIY
culture medium for GCIY-Luc. MKN45 (poorly differentiated
adenocarcinoma), MKN45-Luc expressing luciferase, KATO-III
(signet ring carcinoma), NUGC-3 (poorly differentiated adeno-
carcinoma), and MKN1 (adenosquamous carcinoma) cell lines
were purchased from the Japanese Collection of Research
Bioresources Cell Bank (JCRB). These cell lines were cultured
in RPMI-1640 medium supplemented with 10% FBS and 1% P/
S. The molecular characteristics of the GC cell lines are summar-
ized in supplementary table C.
Immunofluorescent staining
Cell components in peritoneal washes were re-suspended in
RPMI-1640 supplemented with 10% FBS. Then, the total num-
ber of viable cells was counted, and the cells were infected with
TelomeScan at 1 MOI for 24 hours at 37ºC to visualize cancer
cells as GFP-positive cells.24–26 The cells were further stained
with Alexa Fluor 647-conjugated anti-human CD45 antibody
(BioLegend, 304056, RRID: AB_2564155), phycoerythrin (PE)-
conjugated anti-human CD14 antibody (BioLegend, 301805,
RRID:AB_31418), and PE-conjugated anti-human CD163 anti-
body (BioLegend, # 333606, RRID:AB_1134002) as markers of
leukocytes, macrophages, and TAMs, respectively. Nuclei
were stained with 4ʹ, 6-diamidino-2-phenylindole (DAPI).
Immunofluorescent staining was observed under an inverted
fluorescence microscope (IX71; Olympus).
Flow cytometry
The samples were washed with PBS containing 2% FBS and
centrifuged at 300 × g, 4°C for 5minutes. Dead cells were stained
with APC-Cy7-conjugated Zombie NIR (BioLegend, #423105),
and the cells were subsequently stained with the following sur-
face markers for 30 minutes at 4°C: Alexa Fluor 647-conjugated
anti-human CD45 antibody (BioLegend), FITC-conjugated anti-
human CD14 antibody (BioLegend, #301803, RRID:
AB_314185), and PE-conjugated anti-human CD163 antibody
(BioLegend). As the controls, IgG-isotype control antibodies
(BioLegend, #400112) were used. Cells were analyzed by flow
cytometry (FACS Array, Becton Dickinson), and data were
reanalyzed with Flow Jo software (Tree Star).
Migration and invasion assay
The migration assay was performed using transwell 24-well
plates with 8-μm pore polyethylene terephthalate (PET) track-
etched membranes (CORNING). Matrigel-coated filters
(CORNING, BioCoat Matrigel invasion chamber) were used
for the invasion assay. Cancer cells were indirectly co-cultured
with or without TDMs (ratio of TDMs/GC cells, 2/1) using
transwell 6-well plates with 4-μm pore PET track-etched mem-
branes (CORNING) for 48 hours. Then, cells (GCIY: 5 × 10⁴,
MKN45: 1 × 10⁵, MKN1: 1 × 10⁴) were plated in the upper
chamber with 500 μl MEM or RPMI-1640 containing 0.1%
FBS. The lower chamber was filled with MEM or RPMI-1640
containing 15% or 10%FBS, respectively. After incubation for
24 hours at 37°C and 5% CO2, migrating and invading cells
were fixed with 4% paraformaldehyde and stained with 0.5%
crystal violet. The number of cells on the lower surface of the
membrane in 5 random fields was counted using a bright field
light microscope. To examine the effect of IL-6 on migration
and invasion ability of GC cells, the same experiment was
performed in the medium containing recombinant human IL-
6 (R & D, Catalog # 206-IL) at a range of 0–100 ng/ml in the
upper chamber (GCIY: 3 × 10⁴, MKN45: 3 × 10⁴) instead of
co-culture with TDMs. After interaction for 48 hours, migrat-
ing and invading cells were counted in the same way.
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XTT assay
The XTT assay (Cell proliferation kit II, Roche Mannheim)
was performed to evaluate the sensitivity to chemotherapy. In
the same way, after co-culture with TDMs, cancer cells were
plated (3 × 103/well) in 96-well plates. The adherent cells were
treated with paclitaxel (Nippon Kayaku Co., Ltd) or 5-FU
(Kyowa Hakko Kirin Co., Ltd) for 48 hours at a range of
0–10 or 0–1000 μM, respectively, and cell viability was eval-
uated. Optical densities were measured at 450 nm and
690 nm. After treatment with the chemotherapeutic agents,
dose-response curves were drawn, and the IC50 values were
determined by GraphPad Prism 8 version 8.00 (GraphPad
Software, Inc.).
Mouse peritoneal dissemination model and in vivo
efficacy of IL-6
Female BALB/c (nu/nu) mice were purchased from CLEA and
housed under sterile conditions. The experiment was started
when the mice were 5 weeks of age. GC cells were inoculated
into the peritoneal cavity, and 3 groups (n = 5/group), the
Mock-group (non-treated), the GCIY-Luc-group (5 × 10⁶),
and the MKN45-Luc-group (5 × 10⁶), were compared. Three
weeks after inoculation, peritoneal washes were collected by
washing the peritoneal cavity with 2 ml of PBS. Then, the
samples were treated the same as patients’ samples and ana-
lyzed by flow cytometry and ELISA for IL-6. Recombinant
human IL-6 protein (R & D, Catalog # 206-IL) at
a concentration of 200 ng/200 μl/body or PBS at a volume
of 200 μl/body was injected into the peritoneal cavity to assess
whether IL-6 accelerates the development of peritoneal dis-
semination. GCIY-Luc (2 × 10⁶) was inoculated into the
peritoneal cavity, and reagents were inoculated (n = 9 – 10/
group) twice a week from the next day. Peritoneal dissemina-
tion was measured by IVIS once a week. To assess the effect of
blockade of IL-6 from mouse macrophages, GCIY-Luc
(5 × 10⁶) was inoculated into the peritoneal cavity, and anti-
mouse IL-6 antibody (Bio X Cell: clone MP5-20F3, # BE0046,
RRID:AB_1107709) or rat IgG-isotype control (Bio X Cell:
clone HRPN, # BE0088, RRID:AB_1107775) was peritoneally
injected at a concentration of 200 μg/200 μl/body (n = 8 – 9/
group) twice a week and evaluated by IVIS as well.
Cytokine and chemokine assays
TDMs (3 × 10⁵) were indirectly co-cultured with GCIY (1 × 10⁵)
for 72 hours using transwell 6-well plates with 4-μm pore PET
track-etched membranes (Corning), and then the cell culture
supernatant mixture was collected by centrifugation. As
a control, the supernatant of the TDM mono-culture (3 × 10⁵)
was used. The assay was performed according to the manufac-
turer’s protocol (Human Cytokine/Chemokine Array, catalog
# ARY005B, #ARY017, R&D Systems).
To investigate the humoral factors in the peritoneal cavity,
the peritoneal washes were obtained from mice with or with-
out peritoneal dissemination of GC, as described above. The
washes were analyzed with Mouse Cytokine Array Kit (R&D
Systems, #ARY006), Mouse Chemokine Array Kit (R&D
Systems, #ARY020), and Mouse Angiogenesis Array Kit
(R&D Systems, #ARY015).
ELISA for human IL-6
The IL-6 levels of the cell culture supernatant were deter-
mined using enzyme-linked immunosorbent assay (ELISA)
kits (Human IL-6, catalog # D6050, R&D Systems) according
to the manufacturer’s instructions. Each measurement was
repeated in triplicate, and the average value was recorded
(pg/mL). In the in vitro experiment, to mimic the intraper-
itoneal status, a large number of TDMs (3 × 10⁵) was stimu-
lated with a small number of GCIY (1 × 10⁴) for 72 hours.
Then, the IL-6 concentration in the cell culture supernatant
mixture was determined and compared with the mono-
culture of TDMs or GCIY. Other GC cell lines (KATO-III,
MKN45, and NUGC3) were also subjected to the same experi-
ment. Furthermore, to evaluate the effect of macrophages
depending on cell number, macrophages (5, 10, 20, and
30 × 10⁴) were co-cultured with GCIY (1 × 10⁴). The cell
culture supernatant mixture was then collected, and the assay
was performed. Moreover, in the in vivo experiment, mouse
peritoneal wash was analyzed for IL-6 (Mouse IL-6
Quantikine ELISA Kit, R&D Systems, # M6000B). A value of
IL-6 less than detectable sensitivity was defined as one, and
a value of more than 4 pg/ml, which is a serum reference
value, was defined as positive.
Western blotting
GCIY was co-cultured with TDMs (ratio of TDMs/GCIY: 0, 2, 5,
10) or cultured in medium containing recombinant human IL-6
at a range of 0–100 ng/ml for 48 hours. Cells were washed with
cold PBS and lysed with the SDS buffer containing protease
inhibitors (cOmplete Mini, Roche Diagnostics GmbH,
#11836153001). Equivalent amounts of protein from whole-cell
lysates were loaded into each lane of 10% SDS–polyacrylamide
gel and electrophoretically transferred to Hybond-
polyvinylidene difluoride transfer membranes (GE Healthcare
UK Ltd.). Membranes were incubated with the following pri-
mary antibodies overnight at 4°C: anti-signal transducer and
activator of transcription 3 (STAT3; rabbit monoclonal IgG,
diluted 1:1000; Cell Signaling Technology, # 14801, RRID:
AB_2798618) and anti-phosphorylated STAT 3 (p-STAT3;
Rabbit monoclonal IgG, diluted 1:2000; Cell Signaling
Technology, #9145, RRID:AB_2491009). Equal loading of sam-
ples was confirmed by probing with anti–β-actin antibody
(Sigma-Aldrich, #A5441). Membranes were subsequently incu-
bated with secondary antibodies for 1 hour. Peroxidase activity
of secondary antibodies was detected using an ECL prime
Western Blotting Detection Reagent (GE Healthcare UK Ltd.,
#RPN2232) and visualized using an Amersham Imager 600 (GE
Healthcare UK Ltd.) according to the manufacturer’s protocol.
Statistical analysis
Survival curves were estimated using the Kaplan-Meier method
and compared using the log-rank test. P values < .05 were con-
sidered significant. Statistical analysis was performed with JMP®
e1671760-10 S. SAKAMOTO ET AL.
software (JMP version 11, SAS Institute). Patient clinicopathologi-
cal data were obtained from medical records and analyzed by
Student’s t-test and Pearson’s chi-squared test. The analysis for
IC50 was performed using GraphPad Prism 8 (GraphPad
Software, Inc).
Abbreviations
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